GlassScriptPhysician profile
Lucy A Sourial
NPI 1255306403
$3,722.11
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $48.20 · 2021: $417 · 2022: $863 · 2023: $882 · 2024: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527 · Education: $4.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.69 |
| Education | $4.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $940.20 | 2020-2024 | Breztri, Airsupra, Farxiga |
| Gilead Sciences, INC. | $396.18 | 2022-2023 | Descovy |
| E.R. Squibb & Sons, L.L.C. | $386.61 | 2019-2023 | Opdivo |
| Incyte Corporation | $279.69 | 2019-2021 | |
| Lilly USA, LLC | $188.60 | 2019-2023 | Emgality, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $175.84 | 2022 | |
| Celgene Corporation | $142.26 | 2019-2023 | Reblozyl |
| Exelixis INC. | $132.33 | 2022 | |
| Novo Nordisk INC | $129.29 | 2023 | Rybelsus |
| Teva Pharmaceuticals USA, INC. | $104.68 | 2019 | |
| Janssen Pharmaceuticals, INC | $103.56 | 2021-2022 | |
| Glaxosmithkline, LLC. | $82.37 | 2019-2022 | |
| Alkermes, INC. | $78.41 | 2019-2022 | |
| Amgen INC. | $74.66 | 2019 | |
| Abbvie INC. | $55.12 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $46.89 | 2019 | |
| Dova Pharmaceuticals | $44.10 | 2021 | |
| Abbott Laboratories | $36.75 | 2021-2022 | |
| Esperion Therapeutics, INC. | $36.16 | 2021 | |
| Astellas Pharma US INC | $30.39 | 2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.08 | 2019 | |
| Exact Sciences Corporation | $24.95 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $24.39 | 2021 | |
| Genentech USA, INC. | $24.31 | 2019 | |
| Kyowa Kirin, INC. | $23.18 | 2023 | Poteligeo |
| Avanos Medical | $23.06 | 2022 | |
| Mirati Therapeutics, INC. | $22.44 | 2023 | Krazati |
| Seagen INC. | $21.26 | 2021 | |
| Sumitomo Pharma America, INC. | $18.81 | 2023 | Orgovyx |
| Amarin Pharma, INC. | $18.13 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.77 | 2019 | |
| Merck Sharp & Dohme LLC | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Sourial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.